METASTATIC PANCREATIC ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets genetic weakness in tough pancreatic cancer
Disease control Recruiting nowThis phase 3 trial tests whether adding setidegrasib (ASP3082) to standard chemotherapy helps people with a specific KRAS G12D mutation in metastatic pancreatic cancer live longer. About 614 adults will be randomly assigned to receive either setidegrasib or a placebo, along with …
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for pancreatic cancer: experimental combo trial launches
Disease control Recruiting nowThis study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets tough pancreatic cancer in 20-Patient trial
Disease control Recruiting nowThis study tests a combination of two drugs, pembrolizumab and olaparib, in people with advanced pancreatic cancer that has spread to other parts of the body. To join, participants must have tumors with high mutation levels or specific DNA repair problems. The goal is to see if t…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for pancreatic cancer: drug cocktail trial launches
Disease control Recruiting nowThis study tests a new combination of drugs for people with advanced pancreatic cancer that has spread or come back. The treatment includes an experimental antibody (BMS-986340) plus immunotherapy and two chemotherapy drugs. The goal is to see if this mix is safe and shrinks tumo…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for tough pancreatic cancer: targeted drug combo under study
Disease control Recruiting nowThis study tests whether adding a targeted drug called panitumumab to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS wild-type) live longer. About 94 adults whose cancer has spread or can't be removed will be randomly assigned to get c…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New triple therapy targets tough pancreatic cancer
Disease control Recruiting nowThis study is for people with metastatic pancreatic cancer that has spread. It tests a new combination of three drugs (S-1, nab-paclitaxel, and gemcitabine) to find the safest and most effective dose. About 70 participants will take part to see how well the treatment shrinks tumo…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Tiny bubbles carrying gene-targeting drugs take on deadly pancreatic cancer
Disease control Recruiting nowThis early-phase study tests a new treatment for people with advanced pancreatic cancer that has spread and has a specific mutation called KRAS G12D. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the mutated gene. The goal is to find the best…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New chemo cocktail aims to shrink pancreatic tumors
Disease control Recruiting nowThis study compares two chemotherapy regimens for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. One group gets NALIRIFOX (a mix of four drugs) every two weeks, while the other gets a modified version of gemcitabine, nab-paclitaxel, and ci…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Two-Drug sequence aims to extend life in pancreatic cancer
Disease control Recruiting nowThis study tests whether giving two different chemotherapy combinations one after the other works better than the standard single combination for people with metastatic pancreatic cancer. About 162 adults aged 18 to 75 with confirmed disease will be randomly assigned to either th…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug TR-002 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new chemotherapy drug called TR-002 in about 52 people with advanced solid tumors, including pancreatic cancer that has stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New timing of chemo drugs may boost pancreatic cancer response
Disease control Recruiting nowThis study is testing whether changing the timing of two chemotherapy drugs, gemcitabine and nab-paclitaxel, can improve tumor shrinkage in people with pancreatic cancer that has spread to other organs. About 67 participants will receive the drugs on an optimized schedule. The go…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Anne Noonan • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New cocktail of drugs shows promise for tough pancreatic cancer
Disease control Recruiting nowThis phase 2 trial is testing a combination of five drugs (iparomlimab, tuvonralimab, chidamide, nab-paclitaxel, and gemcitabine) as a first treatment for people with metastatic pancreatic cancer. The study aims to see if this mix can shrink tumors and improve survival. It will e…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Electromagnetic fields join the fight against pancreatic cancer
Disease control Recruiting nowThis study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic canc…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Virtual coaching aims to ease pancreatic Cancer's toll on patients and families
Symptom relief Recruiting nowThis study tests whether telehealth self-management coaching sessions can improve quality of life for people with metastatic pancreatic cancer and their family caregivers. Participants will attend virtual coaching sessions focused on managing physical symptoms, emotional well-bei…
Matched conditions: METASTATIC PANCREATIC ADENOCARCINOMA
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC